According to a post-authorisation safety study, patients with rheumatoid arthritis (RA) over 50 years, with one or more additional cardiovascular risk scores, have an increased risk of developing malignancies following treatment with tofacitinib versus tumour necrosis factor inhibitors (TNFi).

The analysis included 4,362 RA patients who received tofacitinib 5 mg...